RxDoctor Payments Data

Kolawale Oshiyoye, MD

Family Medicine · Martinsburg, WVNPI 1427362383

Payments from drug & device makers

$6,620in general payments, 2019–2025

Across 305 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Johnson & Johnson$832
  • Lilly USA, LLC$795
  • GSK$646
  • Novo Nordisk$609
  • AbbVie$559
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$6,589100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,620 in reported general payments places this provider in the 90th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$216,642
Medicare patients
564
Services billed
2,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$94,148
FarxigaDapagliflozin Propanediol74$70,985
EliquisApixaban141$69,842
TrulicityDulaglutide36$46,880
JardianceEmpagliflozin98$41,609
XareltoRivaroxaban85$37,381
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$35,025
JanuviaSitagliptin Phosphate29$22,458
MounjaroTirzepatide21$20,473
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$18,629
BrilintaTicagrelor52$16,870
Tresiba Flextouch U-200Insulin Degludec12$8,955
Breo ElliptaFluticasone/Vilanterol17$7,058
Spiriva RespimatTiotropium Bromide11$6,042
Albuterol Sulfate HfaAlbuterol Sulfate171$4,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$1,274$109,273158 claims
Novo NordiskOzempic$609$94,14882 claims
PfizerEliquis$226$69,842141 claims
Lilly USA, LLCTrulicity, Mounjaro$795$67,35457 claims
Boehringer IngelheimJardiance, Spiriva Respimat$388$47,651109 claims
GSKTrelegy Ellipta, Breo Ellipta$646$42,08371 claims
Johnson & JohnsonXarelto$832$37,38185 claims
MerckJanuvia$15$22,45829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Martinsburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →